Evotec CSO: BMS Opt In On CNS Compound ‘Augurs Well’ For Discovery Pact

Brings Bristol Myers Additional Program Rights In Neurodegenerative Diseases.

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.